Alexion's Soliris® (eculizumab) Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica (NMO)
July 16, 2013 at 06:59 AM EDT
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that Soliris® (eculizumab), the company's first-in-class terminal complement inhibitor, has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) for the treatment of neuromyelitis optica (NMO), a
